Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22:11:617966.
doi: 10.3389/fonc.2021.617966. eCollection 2021.

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas

Affiliations
Review

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas

Marco Zoccarato et al. Front Oncol. .

Abstract

Patients affected with gliomas develop a complex set of clinical manifestations that deeply impact on quality of life and overall survival. Brain tumor-related epilepsy is frequently the first manifestation of gliomas or may occur during the course of disease; the underlying mechanisms have not been fully explained and depend on both patient and tumor factors. Novel treatment options derive from the growing use of third-generation antiepileptic drugs. Vasogenic edema and elevated intracranial pressure cause a considerable burden of symptoms, especially in high-grade glioma, requiring an adequate use of corticosteroids. Patients with gliomas present with an elevated risk of tumor-associated venous thromboembolism whose prophylaxis and treatment are challenging, considering also the availability of new oral anticoagulant drugs. Moreover, intracerebral hemorrhages can complicate the course of the illness both due to tumor-specific characteristics, patient comorbidities, and side effects of antithrombotic and antitumoral therapies. This paper aims to review recent advances in these clinical issues, discussing the medical management of gliomas through an updated literature review.

Keywords: BTRE; DOACs; edema; epilepsy; glioma; hemorrhages; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Earlier brain CT scan of a 71-year-old man presenting with acute onset of right hemiparesis: note the disproportionate hypodense edematous area surrounding the hematoma, not in accordance with the very acute phase of hemorrhage. An underlying unknown HGG was diagnosed.
Figure 2
Figure 2
Brain MRI scan (A: gadolinium enhanced image B: FLAIR image) of a 53-year-old woman complaining of subacute onset of mild left hemiparesis showing highly vascularized HGG; 8 days later the patient developed headache and brain CT scan (C) showed a wide intralesional bleeding.

References

    1. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme. Oncologist (2009) 14:1131–8. 10.1634/theoncologist.2009-0121 - DOI - PubMed
    1. Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol (2019) 20:110–9. 10.1016/S1470-2045(18)30675-2 - DOI - PubMed
    1. Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: Evidence for a core set of tumor-and treatment-related symptoms. Neuro Oncol (2016) 18:252–60. 10.1093/neuonc/nov166 - DOI - PMC - PubMed
    1. Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol (2017) 18:e330–40. 10.1016/S1470-2045(17)30345-5 - DOI - PubMed
    1. Oberndorfer S, Hutterer M. Palliative care in glioma management. Curr Opin Oncol (2019) 31:548–53. 10.1097/CCO.0000000000000584 - DOI - PubMed

LinkOut - more resources